



WORLD ECONOMIC FORUM



Technology
Pioneer
2007

NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX LIFE SCIENCES AND DR. CASHMAN RECEIVE CANADIAN GOVERNMENT GRANT TO DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE

TORONTO, Ontario – July 22, 2008 – Amorfix Life Sciences (TSX: AMF), a company focused on treatments and diagnostics for brain-wasting diseases and the University of British Columbia (UBC), today announced a research collaboration to develop Alzheimer's treatments based upon the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer's Disease. The research will be aimed at preclinical efficacy studies for both antibody treatments and vaccines and will be conducted in Dr. Cashman's laboratory at the Brain Research Center at the UBC in collaboration with Amorfix scientists, and will be supported by a grant from the Canadian Institutes for Health Research (CIHR).

"Amorfix previously reported the discovery of misfolded SOD1 in Alzheimer's patients. This CIHR funding will help initiate an aggressive program to show that our proprietary antibodies and vaccines can be effective in treating Alzheimer's disease," said Dr. Neil Cashman, Chief Scientific Officer of Amorfix and a Professor of Medicine (Neurology) at UBC. "The repeated recent failures of amyloid-removal agents in Alzheimer's clinical trials strongly suggest that other brain-damaging pathways are important and we believe misfolding of SOD1 plays a critical role in this pathway."

"It is reassuring to receive the scientific validation by the CIHR Review Panel of the merits of targeting SOD1 in Alzheimer's disease," said Dr. George Adams, CEO of Amorfix Life Sciences. "We continue to advance our theranostics business plan to develop both diagnostics and therapeutics against Alzheimer's disease."

SOD1 has a "Jekyll-and-Hyde" nature as it normally plays an important protective role in detoxifying free radicals in the body, but when misfolded can create lethal oxidative free radicals. Amorfix's technology targets misfolded SOD1 through two approaches, a passive infusion of manufactured monoclonal antibodies and an active immunization approach designed to elicit the production of similar antibodies by the patient's own body. Amorfix's technology is based on the premise that the misfolding and aggregation of SOD1 is a principal agent in the death of neurons that occurs in brain-wasting diseases. Amorfix believes that if misfolded SOD1 can be specifically recognized and its toxic activity neutralized by antibodies, brain-wasting diseases could be effectively treated.

CIHR will fund \$227,500 in cash over one year with Amorfix contributing the balance of the \$900,000 program.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings; actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	--